Simon Property Group (SPG), the premier mall REIT, is back in the spotlight following years of impressive total returns. As its share price momentum continues, investors are scrutinizing whether its current valuation still presents an attractive entry point for income and growth.
Cardinal Health (CAH) stock has drawn renewed investor interest following robust financial results, with revenue topping $234 billion and net income near $1.6 billion. The healthcare distributor's shares have rallied over 66% in the past year, though its premium valuation compared to peers is sparking debate among analysts.
Shares of gaming and hospitality REIT VICI Properties have faced recent headwinds, trading near $28 and presenting a significant discount to analyst targets. We examine whether the current valuation gap signals a buying opportunity or reflects deeper sectoral risks.
TD Cowen and H.C. Wainwright have raised price targets on KalVista Pharmaceuticals, expressing confidence in its oral hereditary angioedema treatment ahead of the company's fourth-quarter financial results.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.
As market leadership broadens beyond tech, income-focused investors are turning to high-yield dividend ETFs. Vanguard's suite offers diversified, cost-effective options for building retirement income streams in a changing landscape.
Russian Security Council Secretary Sergei Shoigu, meeting with China's top diplomat Wang Yi in Moscow, reiterated Russia's firm support for Beijing's position on Taiwan, calling it an 'inseparable part' of China. The talks underscore deepening strategic coordination between the two powers amid global tensions.
As the ASX braces for a turbulent week amid rate hike fears, investors are scouring the market for resilient opportunities. We delve into three penny stocks—spanning energy, retail, and healthcare—that combine financial stability with distinct growth narratives for the discerning investor.
RBC Capital reaffirms its Outperform rating on UnitedHealth Group, citing management's commitment to long-term earnings targets, even as a lower-than-expected Medicare Advantage rate proposal triggers a sharp sell-off in the health insurer's shares.
Investment firm Needham & Company has reiterated its Buy rating and $21 price target for TeraWulf (WULF), citing the company's strategic shift from Bitcoin mining to high-performance computing and AI infrastructure as a core growth catalyst.
As the Federal Reserve signals potential rate cuts, income-focused investors are re-evaluating their portfolios. We analyze seven dividend ETFs that offer resilient income streams and capital appreciation potential when bond yields decline.
Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
